Inrebic, a once-daily oral capsule, is the second treatment approved in the U.S. for myelofibrosis. The drug is manufactured by Impact Biomedicines, a subsidiary of Celgene.
The drug, a kinase inhibitor, targets treatment-naive myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells.
The approval is the first new treatment for the disease in nearly a decade.
It also comes as a win for drug giant Bristol-Myers Squibb, which is finalizing its merger with Celgene.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
